Results 51 to 60 of about 14,988 (213)

Rituximab Binding Endows CD20+ Extracellular Vesicles With NK Cell‐Activating Properties in B Cell Lymphoma

open access: yesJournal of Extracellular Vesicles, Volume 15, Issue 8, August 2026.
B cell lymphoma‐derived EVs are intrinsically neutral or suppressive with respect to NK cell activity (panel 1). In the context of rituximab treatment, NK cytotoxicity is enhanced by antibody‐dependent cell‐mediated cytotoxicity (panel 2). Herein we show that, in addition, rituximab recognition of EV‐associated CD20 generates immune complexes that ...
Adrián V. Otero   +19 more
wiley   +1 more source

Guidelines On The Treatment Of Acute Myeloid Leukemia: Associação Brasileira De Hematologia, Hemoterapia E Terapia Celular [PDF]

open access: yes, 2017
381587
Teresa Cristina; Chauffaille   +7 more
core  

PB1910: CHRONIC MYELOID LEUKEMIA AND RELATIONSHIP TO SECONDARY SOLID NEOPLASMS

open access: yesHemaSphere, 2022
M. J. Ramos   +12 more
doaj   +1 more source

Regional Standardization of CLL Management: Results of a Delphi Consensus Process

open access: yesEuropean Journal of Haematology, Volume 117, Issue 2, Page 442-447, August 2026.
ABSTRACT The therapeutic landscape of chronic lymphocytic leukemia (CLL) has been profoundly transformed by the introduction of Bruton tyrosine kinase and BCL‐2 inhibitors. Despite improved survival outcomes, treatment selection remains complex, particularly in older patients with comorbidities, frailty, and increased infectious vulnerability.
Enrica Antonia Martino   +22 more
wiley   +1 more source

Real‐World Outcomes of FLAG‐Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study

open access: yesAmerican Journal of Hematology, Volume 101, Issue 7, Page 1692-1705, July 2026.
ABSTRACT In a large multicenter real‐world cohort, we aimed to evaluate outcomes of FLAG‐Ida salvage therapy for relapsed/refractory (R/R) acute myeloid leukemia (AML) and validated the SALFLAGE prognostic score. We analyzed 1079 adults with R/R AML treated across 112 PETHEMA institutions over 26 years (1998–2024), including patients with primary ...
Gaspar Aspas Requena   +49 more
wiley   +1 more source

PB2228: WHAT IS THE UTILITY OF THE MYSEC-PM ON SECONDARY MYELOFIBROSIS RISK STRATIFICATION IN A REAL LIFE SETTING?

open access: yesHemaSphere, 2023
Pedro Moura   +7 more
doaj   +1 more source

Multiple myeloma: A tale of deregulated transcription factors

open access: yesHemaSphere, Volume 10, Issue 7, July 2026.
Abstract A comprehensive understanding of the molecular mechanisms underlying multiple myeloma (MM) pathogenesis is essential for developing therapeutic strategies that overcome disease heterogeneity and treatment relapse. In this review, we focus on transcription factors (TFs), key regulators of gene expression that play critical roles in normal ...
Nahia Gómez‐Echarte   +5 more
wiley   +1 more source

Síndromes mielodisplásicas: a histopatologia como fator prognóstico

open access: yes, 2001
Bone marrow biopsy allows evaluation of cellularity, abnormal localization of immature precursors and fibrosis in myelodysplastic syndrome. It has been considered important to make diagnosis and prognosis of this disorder.
Romeo, Maura [UNIFESP]   +7 more
core   +1 more source

Switching between complement inhibitors in paroxysmal nocturnal hemoglobinuria: Analysis of strategy, efficacy, and safety

open access: yesHemaSphere, Volume 10, Issue 7, July 2026.
Abstract Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra‐orphan disease. In 2026, approved complement inhibitors (CIs) for PNH include three C5 inhibitors (C5i) and three proximal inhibitors (PIs). Clinical trials for the approved PI pegcetacoplan, iptacopan, and C5i + danicopan had clear protocols for changing from terminal to PI, extrapolated ...
Morag Griffin   +15 more
wiley   +1 more source

ANÁLISE SOROLÓGICA DOS DOADORES DE SANGUE DE UM HEMOCENTRO REFERÊNCIA DO ESTADO DO NORDESTE

open access: yesHematology, Transfusion and Cell Therapy
Introdução: Os hemocomponentes e hemoderivados são originados da doação de sangue por um doador. Toda doação de sangue deve ser altruísta, voluntária e não gratificada.
JIOD Santos   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy